title: Ovarian cancer and antiangiogenic therapy: caveat emptor.
authors.affiliation: Walter Reed National Military Medical Center, Bethesda, MD.
authors.forename: Kate E
authors.initials: KE
authors.lastname: Oliver
authors.affiliation: Inova Fairfax Hospital, Annandale, VA William.McGuire@inova.org.
authors.forename: William P
authors.initials: WP
authors.lastname: McGuire
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007191:Indazoles; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011743:Pyrimidines / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D007191:Indazoles; D011743:Pyrimidines; D013449:Sulfonamides; C516667:pazopanib; D040262:Receptors, Vascular Endothelial Growth Factor